RxDoctor Payments Data

Sandeep Nathan

Cardiovascular Disease · Chicago, ILNPI 1225054588

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by ZOLL Circulation Inc at 36.6% of the total. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$892,434in general payments, 2019–2025

Across 776 payments — averaging $1150.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Circulation Inc$327K
  • Johnson & Johnson$280K
  • Merit Medical Systems Inc$81K
  • Shockwave Medical, Inc$48K
  • Medtronic$41K
  • Terumo Medical Corporation$19K
  • plus $97K from 32 others
$200,564in research payments, 2019–2025

Across 71 payments — averaging $2824.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$134K
  • Abbott$32K
  • Biotronik Inc.$27K
  • Chiesi USA, Inc.$8K
  • ZOLL Circulation Inc$220

What the payments were for

  • Consulting fees$467,89552%
  • Speaking & faculty fees$333,44837%
  • Travel & lodging$61,1707%
  • Food & beverage$29,9213%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$892,434 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$133,679
Medicare patients
278
Services billed
598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab23$23,735
Rosuvastatin Calcium48$1,233
Ezetimibe20$1,034
Metoprolol Succinate31$573
ClopidogrelClopidogrel Bisulfate31$425
Carvedilol20$194
Atorvastatin Calcium16$187
Spironolactone14$161

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →